NYSE: MCKMckesson Corp Stock
$349.40+2.84 (+0.82%)
Updated Mar 27, 2023
MCK Price
$349.40
Fair Value Price
N/A
Market Cap
$47.85B
52 Week Low
$298.69
52 Week High
$401.78
P/E
15.9x
P/B
-19.49x
P/S
0.19x
PEG
N/A
Dividend Yield
0.6%
Revenue
$273.90B
Earnings
$3.14B
Gross Margin
4.6%
Operating Margin
1.6%
Profit Margin
1.1%
Debt to Equity
-26.39
Operating Cash Flow
$5B
Beta
0.77
Next Earnings
May 3, 2023
Ex-Dividend
Feb 28, 2023
Next Dividend
Apr 3, 2023
MCK Overview
McKesson Corporation distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products in the U.S. and internationally. It also provides practice management, technology, clinical support, and business solutions to concology and other specialty practices, as well as consulting services to pharmacies. McKesson was founded in 1833 and is headquartered in Irving, TX.
Zen Score
–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MCK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MCK was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MCK is good value based on its earnings relative to its share price (15.9x), compared to the US market average (21.44x)
P/E vs Market Valuation
MCK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MCK due diligence checks available for Premium users.
Be the first to know about important MCK news, forecast changes, insider trades & much more!
MCK News
Valuation
MCK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
15.9x
Industry
12.24x
Market
21.44x
MCK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MCK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MCK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-19.49x
Industry
49.29x
MCK's financial health
Profit margin
Revenue
$70.5B
Net Income
$1.1B
Profit Margin
1.5%
MCK's Earnings (EBIT) of $4.39B... subscribe to Premium to read more.
Interest Coverage Financials
MCK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$62.7B
Liabilities
$64.8B
Debt to equity
-26.39
MCK's short-term liabilities ($48.01B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MCK's short-term assets ($44.66B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MCK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MCK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.7B
Investing
-$414.0M
Financing
-$1.4B
MCK's operating cash flow ($4.72B)... subscribe to Premium to read more.
Debt Coverage Financials
MCK vs Medical Distribution Stocks
Mckesson Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.